Uni-Bio Science Group

Uni-Bio Science Group Inventory

The Inventory of Uni-Bio Science Group (690.HK) as of Oct 23, 2026 is 33.78 M HKD. In the previous year, Inventory was 36.39 M HKD — a change of -7.19% (lower).

Inventory

33.78 MHKD

YoY

-7.19%

Last updated:

Inventory of Uni-Bio Science Group is 2024 33.78 M HKD. Inventory of Uni-Bio Science Group was 2023 36.39 M HKD. It decreases by -7.19% lower compared to the previous year.

The Uni-Bio Science Group Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2017
13.55 M HKD
Jan 1, 2018
18.52 M HKD
Jan 1, 2019
13.34 M HKD
Jan 1, 2020
16.52 M HKD
Jan 1, 2021
39.71 M HKD
Jan 1, 2022
33.85 M HKD
Jan 1, 2023
36.39 M HKD
Jan 1, 2024
33.78 M HKD
The Uni-Bio Science Group Inventory history
YEARInventoryYoY
33.78 MHKD-7.19%
36.39 MHKD+7.50%
33.85 MHKD-14.75%
39.71 MHKD+140.40%
16.52 MHKD+23.84%
13.34 MHKD-27.97%
18.52 MHKD+36.68%
13.55 MHKD+3.80%
13.05 MHKD+44.00%
9.06 MHKD+14.75%
7.90 MHKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd. generates revenue through four segments: in-house chemical pharmaceutical products like Pinapu, in-house biological pharmaceutical products such as GeneTime and GeneSoft, in-house biological pipeline products including Uni-E4 and Uni-PTH, and third-party pharmaceutical products. The company manufactures and sells its own chemical and biological products while also distributing third-party pharmaceuticals. Its primary customers are healthcare providers and pharmaceutical distributors purchasing these branded products. The firm's revenue streams are directly tied to the production and distribution of these specific branded pharmaceuticals across its operational segments. The in-house chemical pharmaceutical segment focuses on products like Pinapu, which is sold to medical institutions and pharmacies. The biological pharmaceutical segment markets GeneTime and GeneSoft for specialized treatments, targeting hospitals and clinics. The biological pipeline segment develops Uni-E4 and Uni-PTH for future commercialization, while third-party pharmaceutical sales involve distributing external brands without direct manufacturing. These segments collectively drive the company's revenue through product sales and distribution agreements. Uni-Bio Science Group's business model relies on both direct manufacturing of its branded pharmaceuticals and third-party product distribution. The company's revenue comes from the sale of Pinapu, GeneTime, GeneSoft, Uni-E4, and Uni-PTH as well as third-party pharmaceuticals. Healthcare institutions and pharmaceutical distributors are the key buyers of these products across all segments, with the in-house products forming the core of the company's revenue generation strategy. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

Inventory of Uni-Bio Science Group is 33.78 M HKD in 2024.

Inventory of Uni-Bio Science Group changed from 36.39 M HKD to 33.78 M HKD, representing a -7.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Uni-Bio Science Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group